2022
DOI: 10.1016/j.isci.2022.105548
|View full text |Cite
|
Sign up to set email alerts
|

Targeting inflammasome-dependent mechanisms as an emerging pharmacological approach for osteoarthritis therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
8
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 11 publications
(9 citation statements)
references
References 122 publications
1
8
0
Order By: Relevance
“…The results show that resveratrol could delay articular cartilage degeneration by balancing HIF-1α and HIF-2α expressions and promoting chondrocyte autophagy, thereby regulating AMPK/mTOR signaling pathway . Similarly to our study, resveratrol was also reported to induce an inadequate assembly of ASC on the mitochondria and inhibit NF-κB responses, leading to the inactivation of NLRP3 inflammasome. However, the low bioavailability and rapid metabolization made the clinical application of these natural compounds ineffective. ,, PT, a dimethyl ether analog of resveratrol, shows better health effects due to its two dimethyl groups, which increase its bioavailability and result in a longer half-life in vivo . , In particular, several studies suggested that increasing the water solubility of PT significantly improves its oral absorption, thereby promoting the research on the production of highly water-soluble PT-modified compounds and increasing the research potential of PT. Our previous study demonstrated that PT could significantly attenuate renal fibrosis by downregulating NLRP3 inflammasome activation . Similar to the results in this study, PT affected the regulation of the NLRP3 inflammasome by reducing the expression of TGF-β-induced NLRP3.…”
Section: Discussionsupporting
confidence: 75%
“…The results show that resveratrol could delay articular cartilage degeneration by balancing HIF-1α and HIF-2α expressions and promoting chondrocyte autophagy, thereby regulating AMPK/mTOR signaling pathway . Similarly to our study, resveratrol was also reported to induce an inadequate assembly of ASC on the mitochondria and inhibit NF-κB responses, leading to the inactivation of NLRP3 inflammasome. However, the low bioavailability and rapid metabolization made the clinical application of these natural compounds ineffective. ,, PT, a dimethyl ether analog of resveratrol, shows better health effects due to its two dimethyl groups, which increase its bioavailability and result in a longer half-life in vivo . , In particular, several studies suggested that increasing the water solubility of PT significantly improves its oral absorption, thereby promoting the research on the production of highly water-soluble PT-modified compounds and increasing the research potential of PT. Our previous study demonstrated that PT could significantly attenuate renal fibrosis by downregulating NLRP3 inflammasome activation . Similar to the results in this study, PT affected the regulation of the NLRP3 inflammasome by reducing the expression of TGF-β-induced NLRP3.…”
Section: Discussionsupporting
confidence: 75%
“…Inflammation and metabolic disorders play a very important role in the progression of osteoarthritis ( 10 , 11 ). Risk factors, including diabetes, hypertension, and hyperlipidemia, are largely involved in osteoarthritis through the release of inflammatory and adipokines that accelerate the progression of osteoarthritis by driving articular cartilage degeneration and bone marrow lesions ( 12 ). Several theories describe how MetS risk factors affect the progression of OA, such as high blood pressure can cause subchondral ischemia, abnormal lipids can cause lipid deposition in chondrocytes, and high blood glucose can cause oxidative stress and low inflammation, eventually leading to cartilage destruction ( 13 ).…”
Section: Introductionmentioning
confidence: 99%
“…NLRP3 and NLRP1 are important inflammasome components in OA, triggering pathogenic processes in macrophages. Targeting inflammasomes in chondrocytes and fibroblast-like synoviocytes presents a promising strategy for developing OA disease-modifying therapies [38].…”
Section: Discussionmentioning
confidence: 99%